You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 26, 2024

CLINICAL TRIALS PROFILE FOR PREVNAR 13


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for PREVNAR 13

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00227188 ↗ Study Evaluating Prevenar in the Prevention of Invasive Pneumococcal Disease (IPD) in the Paediatric Population in Spain. Completed Pfizer 2003-05-01 The aim of this study is to evaluate the postlicensure effectiveness of Prevnar in the prevention of IPD in the Spanish paediatric population (children younger than 5 years)
NCT00323557 ↗ Immuno-Augmentation With GM-CSF of Pneumococcal Vaccine in Chronic Lymphocytic Leukemia Patients Completed Bayer Phase 2 2004-06-01 The goal of this clinical research study is to see if Leukine(R) (sargramostim) improves the effectiveness of the pneumococcal vaccine, a medicine used to prevent pneumococcal pneumonia, in patients with chronic lymphocytic leukemia (CLL).
NCT00323557 ↗ Immuno-Augmentation With GM-CSF of Pneumococcal Vaccine in Chronic Lymphocytic Leukemia Patients Completed M.D. Anderson Cancer Center Phase 2 2004-06-01 The goal of this clinical research study is to see if Leukine(R) (sargramostim) improves the effectiveness of the pneumococcal vaccine, a medicine used to prevent pneumococcal pneumonia, in patients with chronic lymphocytic leukemia (CLL).
NCT00390130 ↗ Does the Order in Which Vaccines Are Administered Affect Pain Response? Completed The Hospital for Sick Children Phase 4 2006-07-01 The objective of this study is to determine whether there should be a predetermined sequence recommended for administering these two vaccines, with the less painful vaccine being given first.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for PREVNAR 13

Condition Name

Condition Name for PREVNAR 13
Intervention Trials
Multiple Myeloma 3
Leukemia 2
Stage 0 Chronic Lymphocytic Leukemia 2
Stage I Chronic Lymphocytic Leukemia 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for PREVNAR 13
Intervention Trials
Multiple Myeloma 5
Neoplasms, Plasma Cell 4
Leukemia, Lymphoid 4
Leukemia, Lymphocytic, Chronic, B-Cell 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for PREVNAR 13

Trials by Country

Trials by Country for PREVNAR 13
Location Trials
United States 41
Poland 9
Finland 7
Spain 6
United Kingdom 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for PREVNAR 13
Location Trials
Maryland 6
Texas 3
Florida 3
Arizona 2
Ohio 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for PREVNAR 13

Clinical Trial Phase

Clinical Trial Phase for PREVNAR 13
Clinical Trial Phase Trials
Phase 4 2
Phase 3 1
Phase 2 8
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for PREVNAR 13
Clinical Trial Phase Trials
Completed 11
Terminated 4
Active, not recruiting 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for PREVNAR 13

Sponsor Name

Sponsor Name for PREVNAR 13
Sponsor Trials
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 5
National Cancer Institute (NCI) 4
Sidney Kimmel Comprehensive Cancer Center 4
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for PREVNAR 13
Sponsor Trials
Other 23
Industry 10
NIH 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.